Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients (2019)
- Authors:
- USP affiliated authors: GATTAZ, WAGNER FARID - FM ; FORLENZA, ORESTES VICENTE - FM
- Unidade: FM
- DOI: 10.1007/s00406-018-0905-3
- Subjects: DOENÇA DE ALZHEIMER; BIOMARCADORES; LEUCÓCITOS; PROTEÍNAS DA MEMBRANA; PLAQUETAS SANGUÍNEAS; ENZIMAS PROTEOLÍTICAS; GLICOPROTEÍNAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Heidelberg
- Date published: 2019
- Source:
- Título do periódico: European archives of psychiatry and clinical neuroscience
- ISSN: 0940-1334
- Volume/Número/Paginação/Ano: v. 269, n. 8, p. 963-972, 2019
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
BRAM, Jessyka Maria de Franca et al. Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients. European archives of psychiatry and clinical neuroscience, v. 269, n. 8, p. 963-972, 2019Tradução . . Disponível em: https://doi.org/10.1007/s00406-018-0905-3. Acesso em: 19 set. 2024. -
APA
Bram, J. M. de F., Talib, L. L., Joaquim, H. P. G., Sarno, T. A., Gattaz, W. F., & Forlenza, O. V. (2019). Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients. European archives of psychiatry and clinical neuroscience, 269( 8), 963-972. doi:10.1007/s00406-018-0905-3 -
NLM
Bram JM de F, Talib LL, Joaquim HPG, Sarno TA, Gattaz WF, Forlenza OV. Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients [Internet]. European archives of psychiatry and clinical neuroscience. 2019 ; 269( 8): 963-972.[citado 2024 set. 19 ] Available from: https://doi.org/10.1007/s00406-018-0905-3 -
Vancouver
Bram JM de F, Talib LL, Joaquim HPG, Sarno TA, Gattaz WF, Forlenza OV. Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients [Internet]. European archives of psychiatry and clinical neuroscience. 2019 ; 269( 8): 963-972.[citado 2024 set. 19 ] Available from: https://doi.org/10.1007/s00406-018-0905-3 - Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study
- Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression
- Inhibition of phospholipase A2 in rat brain decreases the levels of total Tau protein
- Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease
- Decreased Levels of Circulating Adiponectin in Mild Cognitive Impairment and Alzheimer’s Disease
- Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease
- Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease
- Long-term, low-dose lithium treatment does not impair renal functional in the elderly: A 2 year randomized, placebo-controlled trial followed by single blind extension
- Low Doses of Lithium Changes PKA, AKT and Tau Protein in Cortical and Hippocampal Neurons Cell Culture
- Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression
Informações sobre o DOI: 10.1007/s00406-018-0905-3 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas